TrialAmerican journal of nephrology2017

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.

Finnian R Mc Causland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.